$152.67
0.96% yesterday
NYSE, Dec 26, 10:10 pm CET
ISIN
US3773221029
Symbol
GKOS

Glaukos Corp Stock price

$152.67
+11.94 8.48% 1M
+36.01 30.87% 6M
+73.18 92.06% YTD
+72.88 91.34% 1Y
+106.36 229.67% 3Y
+97.27 175.58% 5Y
+121.45 389.01% 10Y
NYSE, Closing price Thu, Dec 26 2024
+1.45 0.96%
ISIN
US3773221029
Symbol
GKOS
Sector

Key metrics

Market capitalization $8.42b
Enterprise Value $8.31b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 23.07
P/S ratio (TTM) P/S ratio 23.36
P/B ratio (TTM) P/B ratio 12.58
Revenue growth (TTM) Revenue growth 18.70%
Revenue (TTM) Revenue $360.35m
EBIT (operating result TTM) EBIT $-109.89m
Free Cash Flow (TTM) Free Cash Flow $-81.27m
Cash position $262.47m
EPS (TTM) EPS $-2.96
P/E forward negative
P/S forward 22.24
EV/Sales forward 21.96
Short interest 7.75%
Show more

Is Glaukos Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.

Glaukos Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Glaukos Corp forecast:

12x Buy
75%
2x Hold
13%
2x Sell
13%

Analyst Opinions

16 Analysts have issued a Glaukos Corp forecast:

Buy
75%
Hold
13%
Sell
13%

Financial data from Glaukos Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
360 360
19% 19%
100%
- Direct Costs 79 79
15% 15%
22%
282 282
20% 20%
78%
- Selling and Administrative Expenses 218 218
25% 25%
60%
- Research and Development Expense 137 137
0% 0%
38%
-73 -73
5% 5%
-20%
- Depreciation and Amortization 37 37
3% 3%
10%
EBIT (Operating Income) EBIT -110 -110
4% 4%
-30%
Net Profit -150 -150
16% 16%
-42%

In millions USD.

Don't miss a Thing! We will send you all news about Glaukos Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Glaukos Corp Stock News

Neutral
Business Wire
4 days ago
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa™ (Epi-on), its next-generation corneal cross...
Positive
Seeking Alpha
6 days ago
Glaukos Corporation (GKOS) is well-positioned to grow sales at a CAGR of ~20% to FY'27, potentially hitting $680mm in revenues and $90-$100mm post-tax earnings. The stock is currently valued at 21x sales, with high expectations for future growth, but a 27% margin of safety exists at current prices. GKOS's efficient asset base and strong cash conversion support sustainable growth, driven by iDos...
Neutral
Business Wire
10 days ago
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PT in S...
More Glaukos Corp News

Company Profile

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Head office United States
CEO Thomas Burns
Employees 907
Founded 1998
Website www.glaukos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today